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ObituaryProfessor Dame Louise Napier Johnson 1940–2012I first met Louise Johnson in 1965 when I
was a graduate student at Oxford. Doro-
thy Hodgkin had encouraged us all to go
to the Royal Institution in London for the
unveiling of the first X-ray structure of an
enzyme, lysozyme, by David Phillips.
The youngest member of his team was
Louise.
The Royal Institution lecture theater had
steeply stacked rows of seats and I
looked down from the back at David
Phillips way below. The fully extended
polypeptide chain of lysozyme—129
amino acids—was suspended from the
high ceiling and reached the bench where
David had placed the model of the folded
chain. This was only the second protein at
high resolution determined using X-ray
crystallography. I marveled at the
achievement of Nature in folding this
molecule into a globular structure that
was so neatly packed. Phillips identified
the active site as a well-defined groove
in which evolution had conserved the
catalytic residues through many diver-
gently evolved species. But I remember
most vividly the appearance of Louise
Johnson, just finishing her Ph.D., who
gave an articulate and stunning presenta-
tion of the enzyme bound to substrate
analogs (Johnson and Phillips, 1965;
Johnson, 1998). For the first time, we
began to understand how an enzyme
works; in this case, we had strong clues
as to how it selectively cleaved the poly-
saccharide chain.Professor Dame Louise Napier JohnsonLouise Johnson was born
in 1940 at Worcester. She
studied physics at University
College London between
1959 and 1962, moving to
the Royal Institution to com-
plete her Ph.D. in 1966. After
completing her Ph.D., she
moved to Yale in 1966 to
work with Fred Richards, who
was interested in protein
crystallography but also had
a deep interest in the princi-
ples of protein structure and
folding. She contributed with
Hal Wyckoff to the design of
a flow cell system for X-ray
analysis of crystalline proteins
and to the determination ofthe structure of ribonuclease-S at 3.5 A˚
resolution.
In 1967, Louise returned to the UK to
join David Phillips who had been ap-
pointed the Professor of Molecular
Biophysics at Oxford University. At the
same time, the insulin team, led by Guy
and Eleanor Dodson, moved to join David
in Molecular Biophysics, based initially in
the old Zoology building. As we struggled
to define the structure of insulin, Louise
began to work on a huge and extremely
challenging project, the structure of the
regulatory enzyme glycogen phosphory-
lase, the largest protein so far crystallized.
Fred Richards followed Louise across
the Atlantic—I seem to remember he
sailed his own boat—to join the growing
Molecular Biophysics Laboratory and
constructed the first ‘‘Richards Box’’ for
superposing the model on the density,
known in the lab as ‘‘Fred’s Folly.’’ It took
some time before Louise and her team
had data at high enough resolution to
exploit the Richards Box. Only after more
than 20 years could she (Johnson, 1992),
together with Bob Fletterick, who was
also working on the enzyme (Newgard
et al., 1989), fully explain how phosphory-
lation and binding AMP at sites distant
from the active site led to conforma-
tional changes that influenced the activity,
one of the first examples of enzyme regu-
lation by allostery (Johnson and Barford,
1990). And she was still publishing on
phosphorylase 30 years later!Structure 20, November 7, 2012 ªIn 1968, Louise had married Abdus
Salam, the brilliant Pakistani physicist
and future Nobel laureate. The two were
very happy together, perfectly matched
intellectually. They had two children:
Umar in 1974 and Sayyeda in 1982.
Impressively, during this time Louise was
appointed first in 1967 to a University
Demonstratorship in Zoology at Oxford
and to the Janet Vaughan Lectureship in
Biophysics at Somerville College and
then promoted in 1973 to a University
Lecturership and an Additional Fellowship
at Somerville College.
I came to know Louise well when we
worked first on a review and then on
themonograph ‘‘Protein Crystallography’’
(Blundell and Johnson, 1976). Louise
proved to have an impressive knowledge
and a deep understanding of our sub-
ject, which had not been described in
a single volume before. She wrote clearly
and accurately, always willing to debate
topics. She continued to work on her sec-
tions of the book during her pregnancy
and the birth of her son, Umar. The book
was eventually published in 1976, and 36
years later it is selling on eBay at £425.78.
On the retirement of David Phillips,
Louise was the natural successor, be-
coming Professor of Molecular Bio-
physics in theDepartment ofBiochemistry
and Professorial Fellow, Corpus Christi
College, Oxford. In the same year, her
work on enzymeswas recognized by elec-
tion to the Royal Society and in 2003 she2012 Elseviwas made a Dame (DBE) in
the New Year’s Honors List.
During these years, Louise
focused her research on un-
derstanding cell regulation
through phosphorylation, in-
cluding the role of protein
kinases in the cell cycle. She
defined some early crystal
structures of phosphorylase
kinase in complex with a pep-
tide substrate, giving clues
about kinase substrate speci-
ficity (Lowe et al., 1997). She
worked on the structures of
cyclin complexes with the
cell cycle kinase CDK2, learn-
ing much about its activa-
tion and regulation (Hondaer Ltd All rights reserved 1797
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Obituaryet al., 2005). She unraveled the crystal
structure of human CDK7, providing
insights about its protein recognition
properties (Lolli et al., 2004).
These studies provided the basis for
a general model describing how the
protein kinases are regulated. However,
they also provided structural knowledge
of targets for drug discovery in oncology.
Her early work in 1997 on the relatively
nonselective inhibitor staurosporine re-
vealed some of the first details of how
ATP competitive inhibitors interacted with
CDK2 (Lawrie et al., 1997). She developed
an active program in structure-based drug
design with therapeutic applications for
glycogen phosphorylase, the cell cycle
kinases CDK2 and CDK7, and the tran-
scriptional regulator CDK9. Indeed, her
work, particularly that over the past
decade on protein kinase inhibitors (John-
son, 2009), contributed to the develop-
ment of many clinical compounds.
Louise remained fascinated by physical
techniques and in 2003 accepted the role
of Science Director for Life Sciences
at the Diamond Light Source in the UK,
which was commissioned in January
2007. She had exploited synchrotron
X-radiation in macromolecular crystallog-
raphy in her studies of phosphorylase.
She spent 50% of her time with the
University and 50% with Diamond devel-
oping beamlines for macromolecular
crystallography, noncrystalline diffrac-
tion, circular dichroism, and infrared
microspectroscopy (Duke and Johnson,
2010). Together with Professor So Iwata
and Dr. Gwyndaf Evans and in collabora-1798 Structure 20, November 7, 2012 ª2012tion with Imperial College, she created the
Membrane Protein Laboratory funded by
the Wellcome Trust.
Louise had a passionate interest in
international science, spending 4 years
as Chair of the Scientific Advisory Board
of EMBL and several years on the Advi-
sory Board of the Swiss National Centre
for Competence in Research. She played
a role in the development of science
in Islamic countries, lecturing in Iran,
Bangladesh, and Pakistan, and support-
ing the creation of SESAME, the new syn-
chrotron in Jordan. Her election as an
Associate Member of the Third World
Academy of Sciences reflected her
activity and allowed her to network with
a broad range of eminent scientists with
similar interests in science in developing
countries.
Louise remained always generous
with her time, a huge influence on the
emergence of structural biology in the
UK and elsewhere, and gave wonderful
support to the many new labs established
by her students and research colleagues
throughout the world.
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